COVID-19 vaccines and thrombosis with thrombocytopenia syndrome

@article{Lai2021COVID19VA,
  title={COVID-19 vaccines and thrombosis with thrombocytopenia syndrome},
  author={Chih-Cheng Lai and Wen-Chien Ko and Chih-Jung Chen and Po‐Yen Chen and Yhu-Chering Huang and P.-I. Lee and Po-Ren Hsueh},
  journal={Expert Review of Vaccines},
  year={2021},
  volume={20},
  pages={1027 - 1035}
}
ABSTRACT Introduction To combat COVID-19, scientists all over the world have expedited the process of vaccine development. Although interim analyses of clinical trials have demonstrated the efficacy and safety of COVID-19 vaccines, a serious but rare adverse event, thrombosis with thrombocytopenia syndrome (TTS), has been reported following COVID-19 vaccination. Areas covered This review, using data from both peer-reviewed and non-peer-reviewed studies, aimed to provide updated information… 

COVID-19 and Blood Clots: Is it only The Virus to be Blamed? What are new Updates? A Systematic Review

  • M. Mahmood
  • Medicine
    Journal of Cardiology and Cardiovascular Research
  • 2022
SARS-CoV-2 may cause blood clots, but it is not the only reason, and some medicines used to treat patients, and COVID-19 vaccines are added to the list of causes ofBlood clots despite the rare incidence of blood clOTS recorded in vaccinated people.

A review of the safety and efficacy of current COVID-19 vaccines

This study reviewed the efficacy/effectiveness, immunogenicity, and safety profile of the 12 most progressed COVID-19 vaccines and discussed the challenges and prospects of the vaccine-based approaches in a global crisis.

COVID-19 and cardiovascular disease: manifestations, pathophysiology, vaccination, and long-term implication

Cardiovascular involvement in the COVID-19 pandemic is reviewed with respect to clinical features, pathogenesis, long-term effects, and the adverse effects of treatments and vaccines based on the latest evidence.

Case Report: A Case of COVID Vaccine-Induced Thrombotic Thrombocytopenia Manifested as Pulmonary Embolism and Hemorrhagia. A First Reported Case From Slovakia

A case of a young male patient who developed severe thrombocytopenia and pulmonary embolism 12 days after the first dose of the CoVID-19 vaccine is presented, the first known case of VITT in Slovakia.

The Population-Wide Risk-Benefit Profile of Extending the Primary COVID-19 Vaccine Course Compared with an mRNA Booster Dose Program

It is demonstrated that the rate of vaccine efficacy waning has a significant impact on COVID-19 hospitalisations with the greatest effect in populations with lower vaccination coverage, and there was greater benefit associated with a booster vaccination strategy compared to targeting the unvaccinated population, once >50% of the population had received their primary vaccination course.

Potential Anionic Substances Binding to Platelet Factor 4 in Vaccine-Induced Thrombotic Thrombocytopenia of ChAdOx1-S Vaccine for SARS-CoV-2

Five potential anionic substances of the ChAdOx1-S vaccine that can combine with PF4 and trigger VITT are proposed, including the proteins on the surface of adenovirus and the negatively charged impurity proteins expressed by the vaccine.

SARS-CoV-2-induced Host Metabolic Reprogram (HMR): Nutritional Interventions for Global Management of COVID-19 and Post-Acute Sequelae of COVID-19 (PASC)

The ongoing epidemic of the residual, non-viral host metabolic disorders and complications in COVID-19 survivors is explained and the supportive role of specific host system-targeted nutritional interventions to manage PASC, the newly emerged post-COVID metabolic syndrome is attempted.

Vaccination and Mortality of Patients with a Novel Coronavirus Infection (COVID-19): A Global Approach

An increase in VR correlates with a decrease in MpCOV, which was higher in countries where VR were lower when groups of countries with VR of 20–39 %, 40–59 %, 60–79 %, and ≥80 % were compared.

A randomized controlled trial of heterologous ChAdOx1 nCoV-19 and recombinant subunit vaccine MVC-COV1901 against COVID-19

The findings support the use of heterologous prime-boost with ChAdOx1 and protein-based subunit vaccines, and both spike-specific antibody-secreting B and T cell responses were substantially enhanced by theheterologous schedule.

COVID-19: State of the Vaccination

Six vaccines, including two using novel mRNA technology, are EU-listed by the World Health Organisation, and promising published trial data are available for nine more, and efficacy is good, there are various barriers to their global use.

References

SHOWING 1-10 OF 60 REFERENCES

Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination

It is recommended that treatment with platelet transfusions be avoided because of the risk of progression in thrombotic symptoms and that the administration of a nonheparin anticoagulant agent and intravenous immune globulin be considered for the first occurrence of these symptoms.

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

Vaccination with Ch adenoviral vector encoding the spike protein antigen of severe acute respiratory syndrome coronavirus 2 can result in the rare development of immuneThrombotic thrombocytopenia mediated by platelet-activating antibodies against PF4, which clinically mimics autoimmune heparin-induced thromBocy topenia.

Thrombocytopenia and Intracranial Venous Sinus Thrombosis after “COVID-19 Vaccine AstraZeneca” Exposure

Early observations insinuate that the exposure to the “COVID-19 vaccine AstraZeneca” might trigger the expression of antiplatelet antibodies, resulting in a condition with thrombocytopenia and venous thromBotic events, and patients’ treatment should address the thrombo-embolic manifestations, the coagulation disorder, and the underlying immunological phenomena.

Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH.

Based on reports of atypically located thromboses following vaccination with the AstraZeneca COVID-19 vaccine, the Society of Thrombosis and Haemostasis Research has issued guidance statements on the recognition, diagnosis, and treatment of this rare complication.

Treatment options for COVID-19: The reality and challenges

A Review of Treatment of Coronavirus Disease 2019 (COVID-19): Therapeutic Repurposing and Unmet Clinical Needs

Traditional Chinese medicine with antiviral effects on SARS-CoV-2 and immune-modulation is widely used for COVID-19 patients in China, and is worthy of further studies.

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination

Findings in five patients who presented with venous thrombosis andThrombocytopenia 7 to 10 days after receiving the first dose of the ChAdOx1 nCoV-19 adenoviral vector vaccine against coronavirus disease 2019 (Covid-19) suggest that they represent a rare vaccine-related variant of spontaneous heparin-induced thromBocytopensia.

Deep vein thrombosis (DVT) occurring shortly after the second dose of mRNA SARS-CoV-2 vaccine

This is the first reported case of DVT presenting as an adverse event post-SARS-CoV-2 vaccination, and the intense immunological response evoked by the second dose of vaccine could be a trigger for the thrombotic event described.

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older and safety over a median of 2 months was similar to that of other viral vaccines.
...